<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125370">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470404</url>
  </required_header>
  <id_info>
    <org_study_id>2008-05-053</org_study_id>
    <nct_id>NCT01470404</nct_id>
  </id_info>
  <brief_title>Pharmacogenomic Study (Adjuvant Chemotherapy)</brief_title>
  <official_title>Pharmacogenomic Study to Predict Toxicity and Response in Gastric Cancer Patients Treated With Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity
      profile.

      To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor
      suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric
      cancer patients treated with adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>germline polymorphisms in xenobiotic metabolism genes in toxicity profile</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant chemotherapy</arm_group_label>
    <description>Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled on to the adjuvant trial will be considered as candidates for the study.
        Once the patient signed written informed consent, 10cc blood will be drawn in EDTA tube
        for DNA extraction.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gastric cancer patients treated with adjuvant chemotherapy

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>won ki kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mi yeon kwon, RN</last_name>
    <phone>+82-2-3410-1248</phone>
    <email>miyeon.kwon@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mi yeon kwon, RN</last_name>
      <phone>+82-2-3410-1248</phone>
      <email>miyeon.kwon@samsung.com</email>
    </contact>
    <investigator>
      <last_name>won ki Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 12, 2013</lastchanged_date>
  <firstreceived_date>November 9, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Ki Kang</investigator_full_name>
    <investigator_title>Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
